Infarct size reduction to 30 days could result in clinical benefit at one year

Original title: Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: One-year results from the INFUSE-AMI trial. Reference: Stone GW et al. Circ Cardiovasc Interv. 2013;Epub ahead of print.   The intra-coronary infusion of Abciximab added to thromboaspiration seems to improve outcomes at one year in patients undergoing primary angioplasty for ST-segment elevation with anterior<a href="https://solaci.org/en/2013/10/16/infarct-size-reduction-to-30-days-could-result-in-clinical-benefit-at-one-year/" title="Read more" >...</a>

Noncardiac surgery is safe after 6 months after implantation of a DES

Original title: Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. Reference: Hawn MT et al. JAMA 2013;DOI:10.1001 In the patients who underwent non cardiac surgery and had coronary angioplasty with stent history  within 2 years there was not increased in major cardiac events (MACE ) with the exception of those who were<a href="https://solaci.org/en/2013/10/11/noncardiac-surgery-is-safe-after-6-months-after-implantation-of-a-des/" title="Read more" >...</a>

Endoprosthesis for the treatment of type A aortic dissection

Original title: Application of Open Triple-Branch Aortic Arch Stent Graff for Acute Stanford Type A Aortic Dissection Reference: Fei Hua, et; al. Vascular Endovascular Surgery 47;2:109-14 Type A aortic dissection is a disease of high morbidity and mortality, especially in the early hours . Surgery is the treatment of choice but still have a significant complication rate .<a href="https://solaci.org/en/2013/10/08/endoprosthesis-for-the-treatment-of-type-a-aortic-dissection/" title="Read more" >...</a>

Cilostazol reduces restenosis of DES in lesions larger than 40 mm.

Original title: Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the Pooled Analysis of DECLARE Trials). Reference: Seung-Whan Lee et al. Am J Cardiol 2013, article in press. Cilostazol, an inhibitor of phosphodiesterase III , associated with aspirin and clopidogrel showed decrease angiographic restenosis both in conventional stents as well as<a href="https://solaci.org/en/2013/10/07/cilostazol-reduces-restenosis-of-des-in-lesions-larger-than-40-mm/" title="Read more" >...</a>

Paclitaxel eluting balloon . More effective in restenosis of BMS than DES

Original title: A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Referencia: Seiji Habara et al. Am Heart J 2013;166:527-533.e2. Paclitaxel – eluting balloons have recently emerged as an option for treating in-stent restenosis, both conventional stents ( BMS ) and with drugs (DES ).<a href="https://solaci.org/en/2013/09/25/paclitaxel-eluting-balloon-more-effective-in-restenosis-of-bms-than-des/" title="Read more" >...</a>

Usefulness of FFR in coronary bypass intermediate lesions

Original title: Long-term clinical outcome after fractional flow reserve– versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. Reference: Luigi Di Serafino et al. Am Heart J 2013;166:110-8. Bypass coronary angioplasty is often preferred strategy versus re-operation , however it is associated with a greater number of events,  both short and long<a href="https://solaci.org/en/2013/09/24/usefulness-of-ffr-in-coronary-bypass-intermediate-lesions/" title="Read more" >...</a>

Sub intimal recanalization of superficial femoral , femoropopliteal bypass similar results

Original title: Subintimal Recanalization Plus Stenting or Bypass for Management of Claudicants with Femoro-popliteal Occlusions. Reference: Boufi et al. Eur J Vasc Endovasc Surg. Volume 46 Issue 3 September/2013. The main criticism of sub intimal technique is its relative low permeability compared to the surgical technique . Different studies reported a permeability between 56 and 70 % annually .<a href="https://solaci.org/en/2013/09/19/sub-intimal-recanalization-of-superficial-femoral-femoropopliteal-bypass-similar-results/" title="Read more" >...</a>

Difference in mortality with surgery versus angioplasty in diabetic multivessel patients

Original title: Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: A meta-analysis of randomized controlled trials. Reference: Verma S. et al. Lancet Diabetes Endocrinol. 2013;Epub ahead of print. The FREEDOM study was the last of the randomized studies that compared the results of surgery versus coronary angioplasty in diabetic multivessel patients showing a<a href="https://solaci.org/en/2013/09/18/difference-in-mortality-with-surgery-versus-angioplasty-in-diabetic-multivessel-patients/" title="Read more" >...</a>

Primary angioplasty , a race against time

Original title: Door-to-Balloon Time and Mortality among Patients Undergoing Primary PCI. Reference: Daniel S. Menees et al. N Engl J Med 2013;369:901-9. For more than a decade has been ranked , like a race, to the delay times that occur in hospitals until angioplasty is performed in the context of an infarct with ST segment elevation . Several<a href="https://solaci.org/en/2013/09/13/primary-angioplasty-a-race-against-time/" title="Read more" >...</a>

Thromboaspiration in AMI, without benefit to 30 days.

Original title: Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. TASTE trial. Reference: Ole Fröbert et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1308789 One of the biggest challenges of primary angioplasty is to restore normal coronary flow. Thromboaspiration is a relatively simple, quick and cheap it can improve the flow and resolution of ST , however , the<a href="https://solaci.org/en/2013/09/11/thromboaspiration-in-ami-without-benefit-to-30-days/" title="Read more" >...</a>